Back to Search
Start Over
Immune-checkpoint inhibitors in pituitary malignancies.
- Source :
-
Anti-cancer drugs [Anticancer Drugs] 2022 Jan 01; Vol. 33 (1), pp. e28-e35. - Publication Year :
- 2022
-
Abstract
- To date, there are no standardized systemic treatment options for patients with metastatic pituitary carcinoma progressed to chemo and radiation therapy. Immune-checkpoint inhibitors (ICIs) have been successfully assessed in other solid malignancies and could be a concrete hope for these patients. We performed a critical review of the literature aimed to evaluate studies assessing ICIs in pituitary malignancies. We also conducted research about published translational data assessing immune-contexture in these malignancies. Some preliminary reports reported a successful administration of pembrolizumab or the combination between nivolumab and ipilimumab in patients with metastatic ACTH-secreting pituitary carcinomas. Translational data suggest that adenomas secreting growth hormone and ACTH have a suppressed immune-microenvironment, which could be more likely to benefit from ICIs. Immune-checkpoint inhibitors can be an effective treatment in patients with pituitary carcinoma and maybe also recurrent adenoma. Tumors secreting growth hormone and ACTH are more likely to benefit from ICIs due to a different immune-microenvironment.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Adrenocorticotropic Hormone biosynthesis
Antibodies, Monoclonal, Humanized therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Growth Hormone biosynthesis
Humans
Immune Checkpoint Inhibitors administration & dosage
Immune Checkpoint Inhibitors adverse effects
Ipilimumab therapeutic use
Neoplasm Metastasis
Nivolumab therapeutic use
Tumor Microenvironment drug effects
Immune Checkpoint Inhibitors therapeutic use
Pituitary Neoplasms drug therapy
Pituitary Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1473-5741
- Volume :
- 33
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Anti-cancer drugs
- Publication Type :
- Academic Journal
- Accession number :
- 34348358
- Full Text :
- https://doi.org/10.1097/CAD.0000000000001157